DESFLURANE

Details

Stereochemistry	RACEMIC
Molecular Formula	C3H2F6O
Molecular Weight	168.0378
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)OC(F)C(F)(F)F

InChI

InChIKey=DPYMFVXJLLWWEU-UHFFFAOYSA-N

InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H

HIDE SMILES / InChI

Molecular Formula	C3H2F6O
Molecular Weight	168.0378
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30725791 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020118s024lbl.pdf

Desflurane is a non-flammable liquid administered via vaporizer as a general anesthetic. It is halogenated exclusively with fluorine and is very resistant to defluorination. For this reason, it is not associated with nephrotoxicity, as is the case with other inhalational anesthetics. Desflurane is indicated for the induction and/or maintenance of anesthesia and adults, and for maintenance of anesthesia in pediatric patients following the induction with other agents.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
skeletal muscle relaxation 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020118s024lbl.pdf	Primary		Approved 8583	SUPRANE Approved Use Suprane is an inhalation agent indicated for induction and/or maintenance of anesthesia in adults, for maintenance of anesthesia in pediatric patients following induction with agents other than Suprane (desflurane, USP) and intubation. Launch Date 1992

Doses

Dose	Population	Adverse events
0.7 MAC single, respiratory Recommended Dose: 0.7 MAC Route: respiratory Route: single Dose: 0.7 MAC Sources: https://www.fda.gov/media/92113/download	unhealthy, 2-16 Health Status: unhealthy Age Group: 2-16 Sources: https://www.fda.gov/media/92113/download	Other AEs: Airways obstruction, Breath holding... Other AEs: Airways obstruction (4%) Breath holding (3%) Bronchospasm (1%) Coughing (26%) Hiccups (1%) Laryngospasm (13%) Sources: https://www.fda.gov/media/92113/download

AEs

AE	Significance	Dose	Population
Bronchospasm	1%	0.7 MAC single, respiratory Recommended Dose: 0.7 MAC Route: respiratory Route: single Dose: 0.7 MAC Sources: https://www.fda.gov/media/92113/download	unhealthy, 2-16 Health Status: unhealthy Age Group: 2-16 Sources: https://www.fda.gov/media/92113/download
Hiccups	1%	0.7 MAC single, respiratory Recommended Dose: 0.7 MAC Route: respiratory Route: single Dose: 0.7 MAC Sources: https://www.fda.gov/media/92113/download	unhealthy, 2-16 Health Status: unhealthy Age Group: 2-16 Sources: https://www.fda.gov/media/92113/download
Laryngospasm	13%	0.7 MAC single, respiratory Recommended Dose: 0.7 MAC Route: respiratory Route: single Dose: 0.7 MAC Sources: https://www.fda.gov/media/92113/download	unhealthy, 2-16 Health Status: unhealthy Age Group: 2-16 Sources: https://www.fda.gov/media/92113/download
Coughing	26%	0.7 MAC single, respiratory Recommended Dose: 0.7 MAC Route: respiratory Route: single Dose: 0.7 MAC Sources: https://www.fda.gov/media/92113/download	unhealthy, 2-16 Health Status: unhealthy Age Group: 2-16 Sources: https://www.fda.gov/media/92113/download
Breath holding	3%	0.7 MAC single, respiratory Recommended Dose: 0.7 MAC Route: respiratory Route: single Dose: 0.7 MAC Sources: https://www.fda.gov/media/92113/download	unhealthy, 2-16 Health Status: unhealthy Age Group: 2-16 Sources: https://www.fda.gov/media/92113/download
Airways obstruction	4%	0.7 MAC single, respiratory Recommended Dose: 0.7 MAC Route: respiratory Route: single Dose: 0.7 MAC Sources: https://www.fda.gov/media/92113/download	unhealthy, 2-16 Health Status: unhealthy Age Group: 2-16 Sources: https://www.fda.gov/media/92113/download

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Kv1.5 27	CYP2E1 729

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
Kv1.5 42	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/32436224/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19442086/ \| https://pubmed.ncbi.nlm.nih.gov/8214760/	likely

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4445	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4445
ChemicalBook	CB2304120	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2304120
eMolecules	907267	https://www.emolecules.com/cgi-bin/more?vid=907267

PubMed

Title	Date	PubMed
The threshold and gain of thermoregulatory vasoconstriction differs during anesthesia in the dependent and upper arms in the lateral position.	2002-04	11916816
Subcellular localization of trifluoroacetylated liver proteins in association with hepatitis following isoflurane.	2002-03	11873055
The relationship between acceleromyographic train-of-four fade and single twitch depression.	2002-03	11873031
Selective spinal anesthesia versus desflurane anesthesia in short duration outpatient gynecological laparoscopy: a pharmacoeconomic comparison.	2002-03	11867376
Fast-track eligibility of geriatric patients undergoing short urologic surgery procedures.	2002-03	11867375
Phantom anaesthetic vapour.	2002-02	11871975
Effects of desflurane and isoflurane on intestinal tissue oxygen pressure during colorectal surgery.	2002-02	11871946
Transcutaneous electrical stimulation of an auricular acupuncture point decreases anesthetic requirement.	2002-02	11818761
Small-dose selective spinal anesthesia for short-duration outpatient laparoscopy: recovery characteristics compared with desflurane anesthesia.	2002-02	11812696
Anaesthetic agents in paediatric day case surgery: do they affect outcome?	2002-01	11913809
Model-based administration of inhalation anaesthesia. 3. Validating the system model.	2002-01	11883376
Fresh gas flow is not the only determinant of volatile agent consumption: a multi-centre study of low-flow anaesthesia.	2002-01	11881883
Effects of desflurane on jugular bulb gases and pressure in neurosurgical patients.	2002-01	11773817
The assessment of postural stability after ambulatory anesthesia: a comparison of desflurane with propofol.	2002-01	11772801
Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo.	2002-01	11753018
Prevention of PONV with dexamethasone in female patients undergoing desflurane anesthesia for thyroidectomy.	2001-12	11840580
EEG complexity as a measure of depth of anesthesia for patients.	2001-12	11759923
The recovery of cognitive function after general anesthesia in elderly patients: a comparison of desflurane and sevoflurane.	2001-12	11726429
The effects of increasing concentrations of isoflurane and desflurane on pulmonary perfusion and systemic oxygenation during one-lung ventilation in pigs.	2001-12	11726419
Integrated analysis of protein and glucose metabolism during surgery: effects of anesthesia.	2001-12	11717214
Inhalation anaesthetics increase heart rate by decreasing cardiac vagal activity in dogs.	2001-11	11878527
Carbon monoxide production from desflurane, enflurane, halothane, isoflurane, and sevoflurane with dry soda lime.	2001-11	11684991
Prolonged anesthesia with desflurane and fentanyl in dogs during conventional and laparoscopic surgery.	2001-10-01	11601789
Viscosity and density of common anaesthetic gases: implications for flow measurements.	2001-10	11878731
Measuring the costs of inhaled anaesthetics.	2001-10	11878724
Blood solubilities of volatile anesthetics in cardiac patients.	2001-10	11687994
Dynamic changes in blood solubility of desflurane, isoflurane, and halothane during cardiac surgery.	2001-10	11687993
[The effect of propofol vs desflurane on recovery from anesthesia with remifentanil in outpatient surgery].	2001-10	11674983
Goal oriented general anesthesia for Cesarean section in a parturient with a large intracranial epidermoid cyst.	2001-10	11606346
Desflurane confers neurologic protection for deep hypothermic circulatory arrest in newborn pigs.	2001-10	11605939
Interaction of volatile anesthetics with human Kv channels in relation to clinical concentrations.	2001-10	11605938
[Alternatives to nitrous oxide-desflurane].	2001-10	11592028
200 years of nitrous oxide (laughing gas)--and the end of an era?	2001-10	11592024
Oxidative stress status during exposure to propofol, sevoflurane and desflurane.	2001-10	11574369
The convulsant and anesthetic properties of cis-trans isomers of 1,2-dichlorohexafluorocyclobutane and 1,2-dichloroethylene.	2001-10	11574358
Desflurane, sevoflurane, and isoflurane affect left atrial active and passive mechanical properties and impair left atrial-left ventricular coupling in vivo: analysis using pressure-volume relations.	2001-09	11575543
Sub-MAC concentrations of desflurane do not inhibit hypoxic pulmonary vasoconstriction in anesthetized piglets.	2001-09	11546716
Volatile anesthetics give a false-positive reading in chemical agent monitors in the "H" mode.	2001-08	11515322
Effects of desflurane and sevoflurane on length-dependent regulation of myocardial function in coronary surgery patients.	2001-08	11506106
A case report of a fractured healthytooth during use of Guedel oropharyngeal airway.	2001-07	11599628
Use of intravenous opioids to reduce airway irritation during induction of anaesthesia with desflurane.	2001-04	11573648
Prediction of volatile anaesthetic solubility in blood and priming fluids for extracorporeal circulation.	2001-03	11573521
Effects of different concentrations of sevoflurane and desflurane on subcortical somatosensory evoked responses in anaesthetized, non-stimulated patients.	2001-01	11575411
Recovery and neurological examination after remifentanil-desflurane or fentanyl-desflurane anaesthesia for carotid artery surgery.	2001-01	11575408
Model-based administration of inhalation anaesthesia. 2. Exploring the system model.	2001-01	11575406
Intravenous opioids reduce airway irritation during induction of anaesthesia with desflurane in adults.	2001-01	11575399
Model-based administration of inhalation anaesthesia. 1. Developing a system model.	2001-01	11575385
Comparison of the influence of desflurane nitrous oxide anesthesia to propofol nitrous oxide anesthesia on rocuronium bromide induced neuromuscular block.	2001	11732388
A survey on anesthesia for thoracoscopic sympathetic surgery in treatment of hyperhidrosis palmaris in Taiwan.	2001	11695798
Use of remifentanil in combination with desflurane or propofol for ambulatory oral surgery.	2001	11534310

Substance Class	Chemical Created by `admin` on `Wed Apr 02 06:53:37 GMT 2025` Edited by `admin` on `Wed Apr 02 06:53:37 GMT 2025`
Record UNII	CRS35BZ94Q
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DESFLURANE

Official Name

English

SUPRANE

Preferred Name

English

desflurane [INN]

Common Name

English

I-653

Code

English

DESFLURANE [USAN]

Common Name

English

DESFLURANE [VANDF]

Common Name

English

Desflurane [WHO-DD]

Common Name

English

ETHANE, 2-(DIFLUOROMETHOXY)-1,1,1,2-TETRAFLUORO-, (±)-

Systematic Name

English

DESFLURANE [USP MONOGRAPH]

Common Name

English

DESFLURANE [ORANGE BOOK]

Common Name

English

DESFLURANE [USP-RS]

Common Name

English

DESFLURANE [JAN]

Common Name

English

(±)-2-DIFLUOROMETHYL 1,2,2,2-TETRAFLUOROETHYL ETHER

Common Name

English

DESFLURANE [EP MONOGRAPH]

Common Name

English

DESFLURANE [MI]

Common Name

English

DESFLURANE [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N01AB07